2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The myeloid differentiation primary response gene 88 ( MYD88) L265P mutation is a disease‐specific mutation of primary central nervous system lymphoma (PCNSL) among the central nervous system tumors. Accordingly, this mutation is considered a reliable diagnostic molecular marker of PCNSL. As the intra‐operative diagnosis of PCNSL is sometimes difficult to achieve using histological examinations alone, intra‐operative detection of the MYD88 L265P mutation could be effective for the accurate diagnosis of PCNSL. Herein, we aimed to develop a novel rapid genotyping system (GeneSoC) using real‐time polymerase chain reaction (PCR) based on microfluidic thermal cycling technology. This real‐time PCR system shortened the analysis time, which enabled the detection of the MYD88 L265P mutation within 15 min. Rapid detection of the MYD88 L265P mutation was performed intra‐operatively using GeneSoC in 24 consecutive cases with suspected malignant brain tumors, including 10 cases with suspected PCNSL before surgery. The MYD88 L265P mutation was detected in eight cases in which tumors were pathologically diagnosed as PCNSL after the operation, while wild‐type MYD88 was detected in 16 cases. Although two of the 16 cases with wild‐type MYD88 were pathologically diagnosed as PCNSL after the operation, MYD88 L265P could be detected in all eight PCNSL cases harboring MYD88 L265P. The MYD88 L265P mutation could also be detected using cell‐free DNA derived from the cerebrospinal fluid of two PCNSL cases. Detection of the MYD88 L265P mutation using GeneSoC might not only improve the accuracy of intra‐operative diagnosis of PCNSL but also help the future pre‐operative diagnosis through liquid biopsy of cerebrospinal fluid.

          Abstract

          In this manuscript, we developed a rapid genotyping system using a real‐time PCR device (GeneSoC), which could detect MYD88 L265P within 15 min. We could detect MYD88 L265P in 8 PCNSL cases during surgery. The MYD88 L265P mutation could also be detected using cell‐free DNA derived from the cerebrospinal fluid of two PCNSL cases.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

          The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The somatic genomic landscape of glioblastoma.

            We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer. Copyright © 2013 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

              Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is a clinically and genetically heterogeneous disease that is further classified into transcriptionally defined activated B cell (ABC) and germinal center B cell (GCB) subtypes. We carried out a comprehensive genetic analysis of 304 primary DLBCLs and identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data. We integrated these genetic drivers using consensus clustering and identified five robust DLBCL subsets, including a previously unrecognized group of low-risk ABC-DLBCLs of extrafollicular/marginal zone origin; two distinct subsets of GCB-DLBCLs with different outcomes and targetable alterations; and an ABC/GCB-independent group with biallelic inactivation of TP53, CDKN2A loss, and associated genomic instability. The genetic features of the newly characterized subsets, their mutational signatures, and the temporal ordering of identified alterations provide new insights into DLBCL pathogenesis. The coordinate genetic signatures also predict outcome independent of the clinical International Prognostic Index and suggest new combination treatment strategies. More broadly, our results provide a roadmap for an actionable DLBCL classification.
                Bookmark

                Author and article information

                Contributors
                fohka@med.nagoya-u.ac.jp
                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                01 March 2023
                June 2023
                : 114
                : 6 ( doiID: 10.1111/cas.v114.6 )
                : 2544-2551
                Affiliations
                [ 1 ] Department of Neurosurgery Nagoya University Graduate School of Medicine Nagoya Japan
                [ 2 ] Department of Neurosurgery Mie University Graduate School of Medicine Tsu Japan
                [ 3 ] Department of Medical Genomics Center Nagoya University Hospital Nagoya Japan
                [ 4 ] Department of Neurosurgery Daido Hospital Nagoya Japan
                [ 5 ] Division of Cancer Biology Nagoya University Graduate School of Medicine Nagoya Japan
                Author notes
                [*] [* ] Correspondence

                Fumiharu Ohka, Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai‐cho, Showa‐ku, Nagoya 466‐8550, Japan.

                Email: fohka@ 123456med.nagoya-u.ac.jp

                Author information
                https://orcid.org/0000-0002-4344-5750
                https://orcid.org/0000-0002-5569-5626
                https://orcid.org/0000-0002-7797-6453
                https://orcid.org/0000-0003-3746-3191
                Article
                CAS15762 CAS-OA-2344-2022.R1
                10.1111/cas.15762
                10236607
                36859777
                79e0741a-f602-494c-ae68-d2a87326c2d4
                © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 11 February 2023
                : 26 October 2022
                : 14 February 2023
                Page count
                Figures: 5, Tables: 1, Pages: 8, Words: 4781
                Funding
                Funded by: The Hori Science and Arts Foundation
                Categories
                Original Article
                ORIGINAL ARTICLES
                Clinical Research
                Custom metadata
                2.0
                June 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.8 mode:remove_FC converted:02.06.2023

                Oncology & Radiotherapy
                cfdna,liquid biopsy,myd88,primary central nervous system lymphoma,rapid diagnosis

                Comments

                Comment on this article